Contact:

The Quigley Corporation Schedules Investor Conference

DOYLESTOWN, PA, April 10, 2002 -- The Quigley Corporation (Nasdaq: QGLY), a leading developer and marketer of diversified health products, will hold an investor conference on Tuesday, April 16th at the Harvard Club of New York City. The meeting will take place from 5:00 to 7:00 p.m. in the East Reception room of the Harvard Club, which is located at 27 West 44th Street.

Guy J. Quigley, President, Chairman and Chief Executive Officer will review the company's diversification strategy with special emphasis on Quigley Pharma, its wholly-owned ethical pharmaceutical subsidiary.

He will be joined by Richard A. Rosenbloom M.D., Ph.D., the Chief Operating Officer of Quigley Pharma Inc., which was created in January of 2001 to introduce a line of patented prescription drugs. Dr. Rosenbloom will discuss Quigley Pharma's current and future product strategy.

Since its launch, Quigley Pharma has filed patent applications for:

· "Method and Composition for the Topical Treatment of Diabetic Neuropathy," a new formulation for relief of diabetes-related pain - the first of several products that will be submitted to the FDA for approval.

· A second patent filing for a prescription product to relieve sialorrhea (drooling) in patients suffering from Amyotrophic Lateral Sclerosis (ALS), otherwise known as Lou Gehrig's Disease.

· "Method and Composition for Prevention, Reduction and Treatment of Radiation Dermatitis," a potential product to relieve the effects of radiation dermatitis.

To make a reservation request, please phone Maria Rosati at 212-681-1700, extension 109. Reservations are required and seating is limited.

The Quigley Corporation (Nasdaq: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG(TM)) lozenges, gums and sugar free tablets. Cold-Eeze is the only (ZIGG(TM)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

Certain statements in this press release are ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.